CRISPR/Cas13: A potential therapeutic option of COVID-19.
Biomed Pharmacother
; 131: 110738, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-773856
ABSTRACT
The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be considered as the most important current global issue, as it has caused the novel coronavirus disease (COVID-19) pandemic, which has resulted in high mortality and morbidity rates all around the world. Although scientists are trying to discover novel therapies and develop and evaluate various previous treatments, at the time of writing this paper, there was no definite therapy and vaccine for COVID-19. So, as COVID-19 has called ideas for treatment, controlling, and diagnosis, we discussed the application of Clustered Regularly Interspaced Short Palindromic Repeats/Cas13 (CRISPR/Cas13) as a treatment of COVID-19, which received less attention compared with other potential therapeutic options.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
RNA, Viral
/
Genetic Therapy
/
Coronavirus Infections
/
CRISPR-Cas Systems
/
Gene Editing
/
Betacoronavirus
Type of study:
Experimental Studies
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Biomed Pharmacother
Year:
2020
Document Type:
Article
Affiliation country:
J.biopha.2020.110738
Similar
MEDLINE
...
LILACS
LIS